Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...

When families come into the clinic, there is a lot of hand-holding, Spizuoco said, to explain the treatments. She recommends ...

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young ...

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in ...

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.